Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.
Actively Recruiting
Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.
Actively Recruiting
Researchers are evaluating whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy for males aged 11 to 50 years with intermediate and poor-risk metastatic germ cell tumors. This Phase 3 trial aims to improve cure rates for these patients since previous attempts to enhance first-line chemotherapy have been unsuccessful and more toxic. The study is sponsored by the University of Sydney and compares two chemotherapy schedules in this patient population. Participants receive either standard or accelerated BEP chemotherapy. The standard treatment involves 4 cycles every 3 weeks including bleomycin, etoposide, cisplatin, and supportive drugs like pegylated G-CSF or filgrastim, with treatment lasting about 12 weeks. The accelerated arm administers cycles every 2 weeks with similar drugs and doses but includes additional bleomycin after the 4 cycles. Dosages vary based on age and weight, and treatment is personalized by the physician. During the study, participants undergo regular assessments including response evaluations at the end of chemotherapy and at 6 months, safety monitoring for adverse events, and quality of life questionnaires up to 18 months. Researchers measure progression-free survival and overall survival for up to 5 years. The trial involves randomized assignment to treatment groups and careful monitoring of chemotherapy dosing and patient health throughout the study period.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Colorectal cancer rates in the North West are 37% higher than the national average, with poorer overall survival rates. Chemotherapy drugs like fluorouracil, capecitabine, and oxaliplatin are commonly used but can cause chemo-brain, which leads to memory and thinking difficulties. This study aims to assess if an exercise-based prehabilitation program can reduce chemo-brain symptoms, improve brain health, and enhance quality of life in older adults undergoing chemotherapy for colorectal cancer. Participants will take part in a remote exercise program before and during chemotherapy. This includes four 40-minute sessions weekly, with two supervised online sessions and two independent sessions supported by exercise materials. The program combines aerobic and resistance exercises tailored to individual ability, along with daily multivitamin supplements and weekly behavioral support calls. The exercise tolerance and session count will gradually increase and continue throughout the chemotherapy period. Assessments occur at three main visits before chemotherapy, shortly after starting chemotherapy, and soon after completing chemotherapy, with a follow-up three months later. These include fitness tests, blood samples, brain activity monitoring via EEG, cognitive tests, and quality of life questionnaires. Safety is closely monitored, and all procedures are conducted under medical supervision. Participation may improve fitness, mood, and quality of life, while contributing valuable research to future cancer care.
Actively Recruiting
Researchers are studying how platinum-based chemotherapy affects hearing in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based drugs like cisplatin can cause permanent hearing damage, and patients from more deprived backgrounds may face higher risks due to factors like limited healthcare access and greater noise exposure. This study also explores whether hearing loss after chemotherapy is linked to changes in cognitive function, especially considering the impact of chemotherapy-related cognitive problems known as chemo brain. Participants will undergo online hearing and cognitive tests before chemotherapy, within seven days after completing chemotherapy, and again six months later. Hearing is assessed using the Digit Triplet Test, which measures ability to understand speech in noisy environments. Cognitive function is evaluated with tests including the Flanker Test for attention and executive function, and Digit Span tasks for memory. The study will analyze how socioeconomic status, chemotherapy dose, and treatment length influence hearing loss and cognitive changes. During the study, participants will complete short online tests at three time points to measure hearing and cognitive abilities. Researchers will monitor changes in speech reception thresholds and cognitive test scores to understand the relationships between hearing loss, cognition, and social factors. The findings aim to guide future hearing screening and support strategies for cancer patients, with assessments continuing up to six months after chemotherapy ends.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are studying erdafitinib alone or combined with cetrelimab as neoadjuvant treatments before surgery in patients with muscle-invasive bladder cancer MIBC whose tumors have specific FGFR gene alterations. This trial focuses on patients who cannot receive or choose not to have cisplatin-based chemotherapy. The main goal is to measure tumor response rates based on surgical tissue analysis, including the absence of residual disease and tumor downstaging. Participants are assigned to one of two groups erdafitinib alone or erdafitinib combined with cetrelimab given intravenously. Both treatments are given before radical cystectomy surgery, which occurs within 2 to 6 weeks after the last dose. Imaging scans such as CT, MRI, or PET are done before treatment, after treatment, and during follow-up to assess tumor status. During the study, patients will have regular imaging and pathological assessments along with safety monitoring. Researchers will track outcomes like pathological complete response, tumor downstaging, event-free survival, overall survival, and any side effects. Participants are followed for up to 36 months to monitor long-term results and surgery timing. Those with disease progression during treatment will stop the study and receive other care as needed.
1-10 of 19
1